Poor adherence to oral antidiabetic drugs (OADs) in patients with type 2 diabetes (T2D) can
lead to therapy failure and risk of complications. The aim of this study was to produce an …

Importance Sodium-glucose cotransporter 2 (SGLT2) inhibitors significantly reduce deaths
from cardiovascular conditions, hospitalizations for heart failure, and progression of kidney …

Abstract Purpose of Review The burden of obesity worldwide is high and projected to rise.
Obesity increases the risk of several cardiovascular diseases and cardiometabolic risk …

Importance Randomized clinical trials have shown that glucagon-like peptide-1 receptor
agonists (GLP-1 RAs) cause significant weight loss and reduce cardiovascular events in …

Background Heart failure (HF) poses a major public health burden in the United States. We
examined the burden of out‐of‐pocket healthcare costs on patients with HF and their …

Importance Sodium-glucose cotransporter-2 inhibitors (SGLT-2is) have demonstrated many
cardiovascular and kidney function benefits for patients with type 2 diabetes (T2D) …

Importance Glucagon-like peptide 1 (GLP-1) receptor agonists were first approved for the
treatment of type 2 diabetes in 2005. Demand for these drugs has increased rapidly in …

OBJECTIVE We evaluated recent use trends and predictors of first-line antidiabetes
treatment in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS Using two …

Recent advances in type 2 diabetes (T2D) research have highlighted the benefits of sodium‐
glucose co‐transporter‐2 (SGLT‐2) inhibitors, including cardiovascular and renal protection …

Aims To determine national prevalence of sodium-glucose contransporter-2 inhibitor
(SGLT2i) and glucagon-like peptide-1 receptor agonist (GLP1RA) use among adults with …